Two experimental drugs that were being tested in people with dominantly inherited Alzheimer’s disease failed to meet their primary endpoint in a study sponsored by Washington University School of Medicine in St. Louis, US.
Called DIAN-TU, the study was designed to find out whether either treatment could slow the rate of cognitive decline and improve disease-related biomarkers in people known to have a genetic mutation for inherited Alzheimer’s disease.